Welcome to our dedicated page for Adverum Biotechnologies news (Ticker: ADVM), a resource for investors and traders seeking the latest updates and insights on Adverum Biotechnologies stock.
Overview of Adverum Biotechnologies, Inc. (NASDAQ: ADVM)
Adverum Biotechnologies, Inc. is a U.S.-based clinical-stage gene therapy company at the forefront of developing innovative treatments for serious and rare ocular diseases. Leveraging a proprietary adeno-associated virus (AAV)-based directed evolution platform, Adverum aims to provide durable efficacy through sustained expression of therapeutic proteins. The company focuses on developing gene therapies for conditions such as alpha-1 antitrypsin (A1AT) deficiency, hereditary angioedema (HAE), and wet age-related macular degeneration (wet AMD).
Core Business and Achievements:
Adverum is advancing a robust pipeline of gene therapy product candidates. Its lead candidate, ADVM-022 (also known as Ixo-vec), is an intravitreal (IVT) injection designed to deliver long-term aflibercept levels, significantly reducing the need for frequent anti-VEGF injections in patients with wet AMD. ADVM-022 is currently being evaluated in multiple clinical trials, including the Phase 2 LUNA trial, showing promising results in maintaining vision and reducing treatment burdens.
Recent Developments:
- Leadership Appointments: In 2023, Adverum appointed Dr. C. David Nicholson and Dr. Rabia Gurses Ozden to its Board of Directors, bringing extensive pharmaceutical and clinical development expertise.
- Clinical Trials: The company reported positive preliminary efficacy and safety data from the LUNA Phase 2 trial, demonstrating significant reductions in anti-VEGF injection rates and strong safety profiles.
- Financial Growth: Adverum completed a $127.5 million private placement financing, expected to fund operations into late 2025.
Key Products and Partnerships:
Adverum’s flagship product, ADVM-022, is a gene therapy candidate for wet AMD. The company collaborates with strategic partners to enhance its research and development efforts, generating revenue through licensing, research agreements, and collaborations.
With its innovative gene therapy platform and strategic initiatives, Adverum aims to transform the standard of care for ocular diseases, preserving vision and potentially offering functional cures.
Latest News:
- November 2023: Appointment of C. David Nicholson, Ph.D., to Board of Directors.
- February 2024: Presentation of preliminary LUNA Phase 2 data at the Macula Society meeting.
- March 2024: Completion of $127.5 million private placement financing.
- April 2024: Upcoming presentation of 26-week LUNA interim analysis at the ASRS Annual Scientific Meeting.
Adverum Biotechnologies, Inc. (Nasdaq: ADVM) reported its Q2 2021 financial results, revealing a cash position of $363.8 million, expected to last into 2024, a significant extension from prior guidance. R&D expenses rose to $22.6 million, while general and administrative costs surged to $21.9 million. The net loss widened to $44.3 million, or $0.45 per share. The company is prioritizing ADVM-022 development for wet age-related macular degeneration, presenting promising long-term efficacy data but will not pursue its development in diabetic macular edema.
Adverum Biotechnologies (Nasdaq: ADVM) has revised its ADVM-022 development strategy to concentrate on wet age-related macular degeneration (wet AMD) while discontinuing plans for diabetic macular edema (DME). Following safety evaluations from the INFINITY and OPTIC clinical trials, a dose-limiting toxicity (DLT) was observed at high doses in DME patients. Adverum will now focus on a future Phase 2 trial for ADVM-022 in wet AMD utilizing lower doses. The company emphasizes patient safety and plans to present more data in upcoming medical conferences.
Adverum Biotechnologies (Nasdaq: ADVM) announced the appointment of Jon Williams, Ph.D., as vice president of clinical affairs, effective immediately. With 25 years of experience in drug development and regulatory strategies, Dr. Williams will enhance the clinical development of the novel gene therapy candidate ADVM-022. He previously held significant roles at Bausch Health and Aerie Pharmaceuticals, contributing to multiple successful product developments. Additionally, Dr. Williams received a stock option grant of 100,000 shares, vesting over four years, contingent on his continued service.
Adverum Biotechnologies (Nasdaq: ADVM) announces leadership changes as Leone Patterson departs as president and CFO after five years. Christopher J. DeRespino takes over as acting CFO, previously serving as chief business officer, and Peter Soparkar has been appointed COO. Both appointments are effective immediately. The company emphasizes continued focus on patient safety as they prepare to update on the ADVM-022 program in August. Adverum is committed to addressing unmet medical needs in ocular and rare diseases through innovative gene therapies.
Adverum Biotechnologies (Nasdaq: ADVM) announced the appointments of Julie Clark, M.D. as chief medical officer and Brigit Riley, Ph.D. as chief scientific officer, effective immediately. Both leaders will report to Laurent Fischer, M.D.. Their extensive backgrounds in gene therapy will enhance Adverum's efforts in the ADVM-022 program, which focuses on addressing patient safety and expanding the pipeline for ocular diseases. An inducement grant was provided to Dr. Riley, allowing her to purchase 450,000 shares of common stock, with details outlined under Nasdaq regulations.
The Sonic Fund II, L.P., holding approximately 6.8% of Adverum Biotechnologies' common stock (NASDAQ: ADVM), issued a statement on the preliminary voting results from the 2021 Annual Meeting of Stockholders. Sonic expressed gratitude for stockholder support for change and highlighted that proxy advisory firms ISS and Glass Lewis recommended voting for its nominees, citing serious shortcomings in the Company's approach, particularly regarding the ADVM-022 development. Sonic emphasized the need for Adverum to enhance Board accountability and refocus on addressing critical patient needs.
Adverum Biotechnologies (Nasdaq: ADVM) announced the preliminary results of its 2021 Annual Meeting of Stockholders. Shareholders re-elected directors Dawn Svoronos, Reed V. Tuckson, M.D., and Thomas Woiwode, Ph.D., ratified Ernst & Young LLP as independent auditors, and approved executive compensation on an advisory basis. The Board acknowledged shareholder support and feedback while emphasizing patient safety in the ongoing ADVM-022 program. Final voting results will be reported in a Form 8-K submitted to the SEC.
Sonic Fund II, L.P. owns about 6.8% of Adverum Biotechnologies, Inc. (NASDAQ: ADVM) and expresses concerns about stockholder impressions regarding management's potential resignation if Sonic's nominees join the Board. Sonic urges stockholders to disregard these fears unless publicly clarified by Adverum's management. The Fund emphasizes the importance of fiduciary duties under Delaware law and advocates for its independent nominees to work collaboratively with existing Board members to enhance stockholder value and improve patient care.
The Sonic Fund II, L.P., holding 6.8% of Adverum Biotechnologies (NASDAQ: ADVM), urges shareholders to vote for its nominees at the 2021 Annual Meeting on May 12, 2021. Sonic criticizes Adverum for mismanaging the development of ADVM-022, a gene therapy for wet AMD, resulting in a significant drop in stock price (~60% after a serious adverse reaction). Leading proxy advisory firms recommend Sonic's nominees for change in the Board, stressing the need for better oversight and expertise to advance ADVM-022's development and restore shareholder value.
Adverum Biotechnologies Inc. (Nasdaq: ADVM) announced that Jean Bennett, a nominee for its Board of Directors, has opted to withdraw her candidacy ahead of the Annual Meeting scheduled for May 12, 2021. This decision was communicated to CEO Laurent Fischer on May 6, following Dr. Bennett's discomfort with the role. Adverum emphasized its commitment to patient safety in the ongoing review of its ADVM-022 program, aimed at treating serious ocular diseases. The company continues to prioritize this clinical development while the situation unfolds with Sonic Fund II.
FAQ
What is the current stock price of Adverum Biotechnologies (ADVM)?
What is the market cap of Adverum Biotechnologies (ADVM)?
What is Adverum Biotechnologies' main focus?
What is ADVM-022?
What recent leadership changes have occurred at Adverum?
How is Adverum Biotechnologies funded?
What are the recent achievements of ADVM-022 in clinical trials?
When is Adverum's next major presentation?
What is the significance of Adverum's proprietary AAV-based platform?
How does ADVM-022 benefit patients with wet AMD?
What are the financial projections for Adverum Biotechnologies?
What are the main goals of Adverum Biotechnologies?
